NKARTA INC (NKTX) Stock News
NASDAQ:NKTX - Nasdaq - US65487U1088 - Common Stock - Currency: USD
NKTX Latest News, Press Releases and Analysis
Nkarta Announces IND Clearance of Investigator-Sponsored Trial in Myasthenia Gravis and Opening of Enrollment for Ntrust-2
Ntrust-2 open to enroll patients with systemic sclerosis, myositis and ANCA-associated vasculitis across three parallel cohorts Investigator-Sponsored...
Nkarta to Participate in an Upcoming Investor Conference
SOUTH SAN FRANCISCO, Calif., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural...
Nkarta to Participate in an Upcoming Investor Conference
SOUTH SAN FRANCISCO, Calif., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural...
Nkarta Reports Third Quarter 2024 Financial Results and Corporate Highlights
Nkarta Reports Third Quarter 2024 Financial Results and Corporate Highlights
First patient dosed in each of Ntrust-1 and investigator-sponsored clinical trial (IST) of NKX019; enrollment ongoing in both studiesEnrollment in Ntrust-2...
Nkarta to Participate in Upcoming Investor Conference
SOUTH SAN FRANCISCO, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural...
Why Nkarta Stock Is Soaring Today
One analyst is now more bullish about this clinical-stage biotech stock.
NKTX Stock Earnings: Nkarta Beats EPS for Q2 2024
NKTX stock results show that Nkarta beat analyst estimates for earnings per share the second quarter of 2024.
NKTX Stock Earnings: Nkarta Beats EPS for Q2 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Nkarta (NASDAQ:NKTX) just reported results for the second quarter of 2024.Nkart...
Correction: Nkarta Reports Second Quarter 2024 Financial Results and Corporate Highlights
Correction: Nkarta Reports Second Quarter 2024 Financial Results and Corporate Highlights
Enrollment expected to initiate by year-end 2024 in second clinical trial of NKX019 in autoimmune disease, Ntrust-2, for treatment of systemic sclerosis,...
Nkarta Reports Second Quarter 2024 Financial Results and Corporate Highlights
Nkarta Reports Second Quarter 2024 Financial Results and Corporate Highlights
Enrollment expected to initiate by year-end 2024 in second clinical trial of NKX019 in autoimmune disease, Ntrust-2, for treatment of systemic sclerosis,...
Nkarta Announces Initiation of Investigator-Sponsored Clinical Trial Evaluating NKX019 for Systemic Lupus Erythematosus
SOUTH SAN FRANCISCO, Calif., July 24, 2024 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural...
Nkarta Announces Leadership Updates, Appoints Nadir Mahmood as President
Nkarta Announces Leadership Updates, Appoints Nadir Mahmood as President
SOUTH SAN FRANCISCO, Calif., July 16, 2024 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural...
3 Undervalued Stocks Primed for a 2X Return
Discover compelling investment opportunities with top undervalued stocks for high returns leading in healthcare and software.
Nkarta Initiates Clinical Trial of NKX019 in Lupus Nephritis with First Patient in Screening and Announces Pipeline Expansion to Additional Autoimmune Indications
Patient screening underway in Ntrust-1, the first U.S.-based clinical trial of an engineered NK cell therapy for the treatment of lupus nephritis IND...
Nkarta Adds Experienced Leader in Autoimmune R&D, George Vratsanos, M.D., FACR, to Board of Directors
Senior R&D leader brings extensive expertise in immunology, clinical development and translational science...
NKTX Stock Earnings: Nkarta Beats EPS for Q1 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Nkarta (NASDAQ:NKTX) just reported results for the first quarter of 2024.Nkarta...
NKTX Stock Earnings: Nkarta Beats EPS for Q1 2024
NKTX stock results show that Nkarta beat analyst estimates for earnings per share the first quarter of 2024.
Nkarta Reports First Quarter 2024 Financial Results and Corporate Highlights
Nkarta Reports First Quarter 2024 Financial Results and Corporate Highlights
Dosing of first patient with NKX019 for lupus nephritis using disease-tailored lymphodepletion expected in first half of 2024Cash balance of $450.0 million...
Opportunity Alert: 3 Undiscovered Stocks About to Explode on Wall Street’s Radar
Explore these undiscovered stock picks attached with rapid growth in biotechnology, oil and gas, and pharmaceuticals.
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Nkarta, Inc. (NKTX) on Behalf of Investors
